The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of the institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services (HHS).
The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.
Translational medicine develops the clinical practice applications of the basic science aspects of the biomedical sciences; that is, it translates basic science to applied science in medical practice. It is defined by the European Society for Translational Medicine as "an interdisciplinary branch of the biomedical field supported by three main pillars: benchside, bedside, and community". The goal of translational medicine is to combine disciplines, resources, expertise, and techniques within these pillars to promote enhancements in prevention, diagnosis, and therapies. Accordingly, translational medicine is a highly interdisciplinary field, the primary goal of which is to coalesce assets of various natures within the individual pillars in order to improve the global healthcare system significantly.
The British Journal of Cancer is a twice-monthly professional medical journal owned by Cancer Research UK, published on their behalf by Springer Nature's Nature Research.
The European Organisation for Research and Treatment of Cancer (EORTC) is a unique pan-European non-profit clinical cancer research organisation established in 1962 operating as an international association under Belgium law. It develops, conducts, coordinates and stimulates high-quality translational and clinical trial research to improve the survival and quality of life of cancer patients. This is achieved through the development of new drugs and other innovative approaches, and the testing of more effective therapeutic strategies, using currently approved drugs, surgery and/or radiotherapy in clinical trials conducted under the auspices of a vast network of clinical cancer researchers supported by 220 staff members based in Brussels. The EORTC has the expertise to conduct large and complex trials especially specific populations such as the older patient and rare tumours.
Virgil Craig Jordan,, is a scientist with American and British citizenship specializing in drugs for breast cancer treatment and prevention. Currently, he is Professor of Breast Medical Oncology, and Professor of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. More recently his work has branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs). Currently, he plans to develop a new Hormone Replacement Therapy (HRT) for post-menopausal women that prevents breast cancer and does not increase the risk of breast cancer.
The American Society for Bone and Mineral Research (ASBMR) is a professional, scientific and medical society established in 1977 to promote excellence in bone and mineral research and to facilitate the translation of that research into clinical practice. The ASBMR has a membership of nearly 4,000 physicians, basic research scientists, and clinical investigators from around the world.
The Society for Immunotherapy of Cancer (SITC), previously known as the International Society for Biological Therapy of Cancer (iSBTc), is a professional society of scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving outcomes in patients with cancer by advancing the science and application of cancer immunotherapy. Currently, SITC has more than 2,400 members, representing 22 medical specialties from 42 countries around the world, who are engaged in the research and treatment of cancer.
Translational research is research aimed at translating (converting) results in basic research into results that directly benefit humans. The term is used in science and technology, especially in biology and medical science. As such, translational research forms a subset of applied research.
Polysaccharide-K is a protein-bound polysaccharide isolated from the mycelium of Trametes versicolor.
Paolo Boffetta is an Italian epidemiologist. He is doing research on cancer and other chronic diseases, where he contributed to the understanding of the role of occupation, environment, alcohol, smoking and nutrition in disease development.
Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.
Biomedical sciences are a set of sciences applying portions of natural science or formal science, or both, to develop knowledge, interventions, or technology that are of use in healthcare or public health. Such disciplines as medical microbiology, clinical virology, clinical epidemiology, genetic epidemiology, and biomedical engineering are medical sciences. In explaining physiological mechanisms operating in pathological processes, however, pathophysiology can be regarded as basic science.
Waun Ki Hong was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993 to 2005 and as head of the Division of Cancer Medicine from 2001 to 2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.
Carl H. June is an American immunologist and oncologist. He is currently the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research on T cell therapies for the treatment of several forms of cancers. In 2020 he was elected to the American Philosophical Society.
Curtis. C. Harris is the head of the Molecular Genetics and Carcinogenesis Section and chief of the Laboratory of Human Carcinogenesis at the Center for Cancer Research of the National Cancer Institute, NIH.
Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.
Philip Greenberg is a professor of medicine, oncology, and immunology at the University of Washington and head of program in immunology at the Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. He is a co-founder of Juno Therapeutics.
Lisa M. Coussens is an American cancer scientist who is Professor and Chair of the Department of Cell, Developmental and Cancer Biology and Deputy Director for Basic and Translational Research in the Knight Cancer Institute at the Oregon Health & Science University. She served as 2022-2023 President of the American Association for Cancer Research.
